Pneumococcal AMC Timeline

in page functions

Scroll down the timeline to trace the history of the pneumococcal Advance Market Commitment, from concept to launch

2011

1 July 2011: introduction of pneumococcal vaccine in Cameroon

Cameroon introduces vaccine to combat the prime cause of pneumonia.

30 June 2011: introduction of pneumococcal vaccine in Central African Republic

The Government of Central African Republic begins introducing pneumococcal vaccine.

8 April 2011: UNICEF issues second Call for Supply Offers

Based on SDF v3.0, UNICEF issues a second Call for Supply Offers for the procurement of pneumococcal vaccines under the AMC.

4 April 2011: pneumococcal vaccine reaches Democratic Republic of Congo

introduction of pneumococcal vaccine in the Democratic Republic of Congo.

1 April 2011: introduction of pneumococcal vaccine in Honduras

Government of Honduras adds pneumococcal vaccine to its national immunisation programme.

11 March 2011: publication of Strategic Demand Forecast v3.0

March 2011: introduction of pneumococcal vaccine in Mali

January 2011: Guyana, Sierra Leone, Yemen

Three more countries - Guyan, Sierra Leone, Yemen - introduce pneumococcal vaccine into their routine immunisation programmes.

February 2011: Kenya rolls out pneumococcal vaccine

Kenya marks the global roll out of pneumococcal vaccine against the world's leading cause of child death: pneumococcal vaccines on their way to more than 40 developing countries.

2010

December 2010: Latin America roll-out

Developing nations begin introducing new vaccine against major killer within a year of its introduction in rich countries: first roll out of pneumococcal vaccines in Latin America.

June 2010: GAVI Board approves grandfathering of the Advance Market Commitment (AMC)

The GAVI Board approves the grandfathering of the AMC such that all countries that were eligible for GAVI support at the time of signature of the AMC legal agreements – in June 2009 – are still able to access pneumococcal vaccines through GAVI at the AMC terms and conditions.

March 2010: first long-term commitments by manufacturers

The first two companies to make long-term commitments to supply new vaccines against pneumococcal disease. GlaxoSmithKline (GSK) and Pfizer Inc. Supply may start as early as 2010 and at a fraction of the price charged in industrialised countries.

2009

October 2009: pneumococcal AMC receives four offers from vaccine manufacturers

The AMC Secretariat announces that four suppliers have made offers to supply vaccines under the pneumococcal AMC.

September 2009: manufacturers register to participate in the pneumococcal AMC

Panacea Biotect Ltd and the Serum institute of India publicly announce their registration. First call for offers are issued on Friday 4 September 2009.

Mid-June 2009: strategic demand forecast

Based on strategic demand forecast, UNICEF to issue its first call for AMC supply offers this summer.

12 June 2009: AMC becomes operational

The Finance Ministers of Italy, the United Kingdom, Canada, Russia, Norway and The Bill & Melinda Gates Foundation together with GAVI Alliance partners World Bank, UNICEF and WHO, formally activated the AMC pilot project against pneumococcal disease.

2008

November 2008: Monitoring & Evaluation Report released

July 2008: Implementation Working Group report

Donors decided to create an Implementation Working Group (IWG) with the task of recommending a specific proposal for the AMC structure and parameters. Implementation Working Group report recommends terms for the pilot AMC for pneumococcal vaccines.

2 April 2008: Economic Expert Group report

The Economic Expert Group issues its final report

25 March 2008: IAC training meeting, Geneva, Switzerland

The AMC Independent Assessment Committee (IAC) meets for the first time to undergo a training session.

11 January 2008: 3rd Economic Expert Group Meeting

The AMC Economic Expert Group meets for the third time to discuss AMC pricing and design issues.

2007

17 December 2007: TPP approval by WHO Director General

The Target Product Profiles (TPP), endorsed by WHO Strategic Advisory Group of Experts (SAGE) on 6 November 2007, are approved by the WHO Director General. The next step is endorsement by the AMC Independent Assessment Committee (IAC) after which the TPP are considered final and official.

21 November 2007: UNICEF written declaration of interest

UNICEF makes a written declaration of interest to operate as procurement agent for the AMC.

20 November 2007: selection of IAC membership, Geneva, Switzerland

The Independent Assessment Committee (IAC) selection panel meets for the second occasion and finalises the selection of IAC members according to criteria.

2 October 2007: 1st IAC selection panel meeting, Geneva, Switzerland

The Independent Assessment Committee (IAC) selection panel meets for the first time to select IAC members according to specific criteria.

26-27 September 2007: 2nd Economic Expert Group meeting, Washington D.C., US

The AMC Economic Expert Group meets for the second time to discuss AMC pricing and design issues.

11-12 September 2007: TPP committee meeting, WHO, Geneva, Switzerland

The Target Product Profiles (TPP) expert group meets to consider the draft TPP. Leading up to the meeting, several subgroups worked on specific issues and then came to conclusions on the draft TPP.

2-3 August 2007: 1st Economic Expert Group meeting, Washington D.C., US

The AMC Economic Expert Group meets for the first time to discuss AMC pricing and design issues.

16 May 2007: IAC call for applications, Geneva, Switzerland

A call for applications for the AMC Independent Assessment Committee (IAC) was issued on the AMC website. This announcement was also made public through specialised websites, relevant newspapers and the GAVI Alliance’s extensive professional contacts.

9 February 2007: launch of AMC, Rome, Italy

Canada, Italy, Norway, Russia, the United Kingdom, and The Bill & Melinda Gates Foundation commit US$ 1.5 billion to launch the first AMC to help speed the development and availability of a new vaccine which is expected to save the lives of 5.4 million children by 2030. The new initiative will target pneumoccal disease, a major cause of pneumonia and meningitis that kills 1.6 million people every year.

2006

November 2006: 2nd Technical Working Group on AMC, London, UK

Hosted by Her Majesty’s Treasury, the Technical Working Group holds its second meeting and reviews the technical, institutional and financial aspects of a pilot AMC for a pneumoccal vaccine.

7 September 2006: 1st Technical Working Group on AMC, Rome, Italy

Hosted by the Italian Treasury, a Technical Working Group composed of representatives from 15 potential donor countries, a range of other institutions (such as the European Committee, the World Bank, the GAVI Alliance, The Bill & Melinda Gates Foundation and WHO) and industry representatives, meet for a first time and review the technical, institutional and financial aspects of a pilot AMC for a pneumococcal vaccine.

27-28 February 2006: Disease Expert Committee make recommendation on vaccine for AMC pilot, Paris France

An Independent Expert Committee is convened to provide an independent recommendation on which vaccine would be most suitable for the initial AMC pilot. The recommended candidate for the first AMC pilot is pneumcoccal disease. Pneumococcal disease kills around 1.6 million people a year, most of them children. A successful AMC would prevent roughly 5.4 million deaths by 2030.

The Expert Committee also recommend a second AMC for a malaria vaccine be explored to stimulate early research and development investment, and to pilot the impact of the AMC on early stage vaccines. A successful malaria AMC would prevent roughly 2 million deaths by 2030.

January 2006: G7 Finance Ministers launch a constitution process to advise on technical aspects of a pilot AMC

G7 Finance Ministers launch a consultation process to advise on technical aspects of a pilot AMC. The World Bank and the GAVI Alliance provide significant assistance on the design of a pilot AMC. An Advisory Group brought together AMC stakeholders, academics and technical experts in the global health community to provide insight into the technical and structural options for the pilot.

A Disease Expert Committee was also convened to provide an independent recommendation on which vaccine would be most suitable for the initial AMC pilot.

The advisory process concluded that AMCs are a feasible, innovative, sustainable, cost-effective, results-oriented and market-based tool in the fight against global disease and poverty.

2005

2 December 2005: Tremonti Report to G8 Finance Ministers, London, UK

At the G8 Meeting in London, the Italian Minister of Economy and Finance, Guilio Tremonti, presents the report Background papers to Advanced Market Commitments for Vaccines: A new tool in the fight against disease and poverty.

April 2005: publication of the ‘Making Markets for Vaccines’ report

The Center for Global Development (CGD) publishes the report Making markets for vaccines: Ideas for action, lead authors Michael Kremer, Ruth Levine and Owen Barder. The AMC (originally named “Pull Mechanisms”) working group was a policy research group, convened by the Global Health Policy Research Network at the CGD, to explore the feasibility of advance guarantee agreements as a tool for stimulating research, development and production of vaccines for neglected developing-country diseases. Funding for working group meetings, analytic work and consultations was provided under a grant from The Bill & Melinda Gates Foundation. The CGD continued to work on the AMC idea and published additional papers.

close icon

modal window here